A Phase II Study of 9MW3811 in Patients With Pathological Scar

Inclusion Criteria: * Age ≥18 years * Pathological scar with no spontaneous regression over the prior 6 months * At least one scar with modified Vancouver Scar Scale (mVSS) score ≥9 * Willing to use effective contraception for 6 months after last dose (if of childbearing potential) * Provide written informed consent Exclusion Criteria: * Contracture scar causing deformity * All eligible scars either \>10 cm in length and \>5 cm in width, or located exclusively on sun-exposed areas (head, face, hands) * Evidence of scar infection or active systemic infection requiring treatment * Use of anti-scar medications (e.g., corticosteroids, immunosuppressants) or anti-scar procedures (surgery, laser, radiation, etc.) within 4 weeks prior to first dose * Prior treatment with IL-11 cytokine or IL-6 family targeted therapy (e.g., tocilizumab) within specified washout periods * Participation in another interventional study within 28 days * Positive serology for HBV, HCV, HIV, or syphilis with clinical significance * History of severe allergy or known hypersensitivity to study drug components * Clinically significant laboratory abnormalities (eGFR \<90 mL/min/1.73m², PLT \<100×10⁹/L, QTc \>450/470 ms, bilirubin \>1.5×ULN, AST/ALT \>1.5×ULN) * Alcohol or drug abuse within 1 year * Pregnancy, breastfeeding, or unwillingness to use contraception * Any other condition that, in the investigator's judgment, would compromise subject safety or study compliance